Biotech company DEINOVE has promoted Alexis Rideau to the position of Chief Executive Officer. Mr. Rideau has been Deputy Chief Executive since May 2020, but will assume his new role effective January 8, 2021. Interim Chief Executive Officer Charles Woler will revert to his role as Chairman of the Board of Directors.
“The Board of Directors and I confirm our full confidence in Alexis,” said Mr. Woler. “Since his entry in the company, he has driven the momentum we were expecting from his appointment as Deputy Chief Executive Officer of DEINOVE. In just a few months, he has strengthened the Company's positioning in the antimicrobial field and worked to promote DEINOVE's scientific capabilities to its current and future partners. He is now the Chief Executive Officer of this biotech company with high potential in the race against antimicrobial resistance.”
Mr. Rideau has more than 15 years of experience as a business analyst and developer. Prior to joining DEINOVE, he served as strategic partnership manager for health tech company BIOASTER, where he was responsible for strategic partnerships, contract negotiation and corporate strategy.
“I would like to thank Charles Woler and all the members of the Board of Directors for renewing their confidence in me,” said Mr. Rideau. “Since last May, I have been working on the operating transformation to ensure that it becomes a leading driver of innovation in the exploration and exploitation of microbial biodiversity. The energy and determination of DEINOVE's teams made it possible for me to take up my position under optimal conditions, despite the context of the COVID-19 pandemic. Together we are fully committed to developing DEINOVE as a major player in the generation of new antimicrobials.”